ADC Therapeutics S.A. (ADCT) Financial Analysis & Valuation | Quarter Chart
ADC Therapeutics S.A. (ADCT)
ADCTPrice: $4.13
Fair Value: 🔒
🔒score
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B... more
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (AD... more
Description
Shares
| Market Cap | $511.61M | Exchange | NYSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CH | CEO | Ameet Mallik |
| IPO Date | 2020-05-18 | CAGR | 0.69% |
| Employees | 263 | Website | www.adctherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ADCT chart loading...
Fundamentals
Technicals
| Enterprise Value | $603.46M | P/E Ratio | -2.93 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.37 | P/B Ratio | -0.13 |
| P/CF Ratio | -0.24 | P/FCF Ratio | -0.19 |
| EPS | $-1.41 | EPS Growth 1Y | -39.33% |
| EPS Growth 3Y | -32.87% | EPS Growth 5Y | -58.09% |
| Revenue Growth 1Y | 5.39% | Gross Margin | 0.93% |
| Operating Margin | -1.82% | Profit Margin | -2.24% |
| ROE | 0.82% | ROA | -0.52% |
| ROCE | -0.53% | Current Ratio | 4.93 |
| Quick Ratio | 4.66 | Cash Ratio | 4.1 |
| Debt/Equity | -0.59 | Interest Coverage | -5.73 |
| Altman Z Score | -6.37 | Piotroski Score | 1 |